|Bid||65.90 x 1100|
|Ask||66.75 x 900|
|Day's range||64.98 - 66.36|
|52-week range||53.63 - 71.70|
|Beta (5Y monthly)||0.12|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||1.44 (2.22%)|
|Ex-dividend date||24 Feb 2022|
|1y target est||72.40|
FDA grants emergency approval to Pfizer's COVID-19 vaccine for use in children 5- to 11-year old and approves Lilly's (LLY) novel diabetes treatment, Mounjaro (tirzepatide).
Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.
AstraZeneca (AZN) partners with a U.K.-based biotech company to develop monoclonal antibodies targeting the COVID-causing virus.